Research indicates new ways of developing artificial blood product
This article was originally published in Clinica
The latest studies into artificial blood have pinpointed new ways of making a cell-free form of haemoglobin that can carry oxygen more effectively. These findings could lead to a range of blood substitutes far more effective than those developed so far.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.